EP1.04-43 The Significance of NY-ESO 1 Seropositivity and Influence on NSCLC Patients Survival

Abstract

21 patients die due to cancer (mortality: 63.6%). At 12 months, progression-free survival was 33.3% in pembrolizumab and 64% in nivolumab. Conclusion: Immunotherapy brought higher survival rate to NSCLC, with good tolerability in most cases, maintaining and improving the quality of life. However, given the disparities between responses, acknowledgment of new targets and biomarkers will make the patient selection for immunotherapy more accurate.